SCYNEXIS Commends the New York Times for its Reporting on Candida auris and Other Drug-Resistant Pathogens
Two articles published in the New York Times on April 6, 2019 highlight Candida auris and its significant global public health threat
SCYNEXIS reaffirms its mission to develop ibrexafungerp as a novel antifungal to address serious infections caused by Candida auris and other resistant fungal pathogens
Two case studies of patients with Candida auris infections successfully treated with oral ibrexafungerp will be presented this week at ECCMID 2019
JERSEY CITY, N.J., April 8, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today commended the New York Times for its reporting on Candida auris and the major global health issues caused by drug-resistant pathogens. The two articles published in the New York Times on April 6, 2019 are below:
- A Mysterious Infection, Spanning the Globe in a Climate of Secrecy
- Fungus Immune to Drugs Quietly Sweeps the Globe
- The rise of Candida auris embodies a serious and growing public health threat: drug-resistant germs.
- What You Need to Know About Candida Auris
- C. auris is a mysterious and dangerous fungal infection that is among a growing number of germs that have evolved defenses against common medicines. Here are some basic facts about it.
"We at SCYNEXIS understand the significant threat that Candida auris poses to human health and we believe that our lead investigational drug product, ibrexafungerp, can play a major role in combating this growing, global, public health threat," said Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS. "Ibrexafungerp has already successfully treated patients with Candida auris infections in our Phase 3, open-label CARES trial, with this new clinical evidence building on the potent activity against Candida auris demonstrated by ibrexafungerp in multiple preclinical studies.Two case studies from the CARES trial, in which oral ibrexafungerp cleared Candida auris from infected patients, will be presented at ECCMID 2019 later this week. We remain committed to developing ibrexafungerp to treat this new, often multidrug-resistant Candida species and stand ready to do our part to assist the global community in responding to this public health threat."
As previously announced, ibrexafungerp will be showcased in six presentations, including the Candida auris case studies, at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 13-16, 2019, in Amsterdam, Netherlands.
The poster titled "Successful Treatment of Two Patients with Candida auris Candidemia with the Investigational Agent, Oral Ibrexafungerp (formerly SCY-078) from the CARES Study" (L0028), will be presented by Deven Juneja, MD on Saturday, April 13, 2019 from 3:30-4:30pm CET. The poster presents clinical findings for two patients with Candida auris candidemia enrolled in the CARES study who were successfully treated with oral ibrexafungerp. Both patients had multiple co-morbidities, were admitted to the ICU and were diagnosed with Candida auris in the bloodstream. Both of these difficult-to-treat candidemia cases responded positively to oral ibrexafungerp, with clearance of the Candida auris infection at the end of treatment. Ibrexafungerp was well-tolerated by both patients.
SCYNEXIS, Inc. (NASDAQ:SCYX) is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies. The SCYNEXIS team has extensive experience in the life sciences industry, having discovered and developed more than 30 innovative medicines over a broad range of therapeutic areas. SCYNEXIS's lead product candidate, ibrexafungerp (formerly known as SCY-078), is a novel IV/oral antifungal agent in Phase 3 clinical and preclinical development for the treatment of multiple serious and life-threatening invasive fungal infections caused by Candida, Aspergillus and Pneumocystis species. For more information, visit www.scynexis.com.
Forward Looking Statement
Statements contained in this press release regarding expected future events or results are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks inherent in SCYNEXIS's ability to successfully develop and obtain FDA approval for ibrexafungerp. These and other risks are described more fully in SCYNEXIS's filings with the Securities and Exchange Commission, including without limitation, its most recent Annual Report on Form 10-K under the caption "Risk Factors" and other documents subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. SCYNEXIS undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
George E. MacDougall
SOURCE SCYNEXIS, Inc.
Released April 8, 2019